Search

In recently published draft guidance NICE has approved the routine use of another drug combination for some people with secondary breast cancer.  Palbociclib, also known as Ibrance, is a targeted drug made by Pfizer and is now recommended in combination with fulvestrant for the treatment of hormone receptor positive HER2 negative secondary breast cancer when hormone therapy has already been given.  Palbociclib, a cyclin-dependent kinase 4 and 6 inhibitor, works to stop cancer cells from dividing and growing by inhibiting proteins in them.  It has been available through the Cancer Drugs Fund since 2020 but will now be available for routine use.